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Introduction. Immunological factors seem to play a pivotal role in Adult Onset Still’s Disease (AOSD). Among all, IL-18 cytokine
is overexpressed and drives the inﬂammatory process. Objective. We aimed to investigate the levels of IL-18 in sera of Italian
patients with AOSD and to assess its possible role as a marker of disease activity. Methods. IL-18 serum levels were determined
by ELISA in 26 Italian patients with AOSD. Disease activity was assessed using Pouchot’s criteria. As controls, 21 patients with
Rheumatoid Arthritis (RA), 21 patients with Sjogren’s Syndrome (SS), 20 patients with Systemic Lupus Erythematosus (SLE), and
21 healthy subjects (normal human sera, NHS) were evaluated. Results. IL-18 serum levels were signiﬁcantly higher in patients
with active AOSD than in non-active (P = 0.001) and control groups (RA P = 0.0070, SS P = 0.0029, SLE P = 0.0032, NHS
P = 0.0004). A signiﬁcant correlation between IL-18 serum levels and disease activity (P<0.0001), and laboratory parameters as
ferritin (P = 0.0127) and C-reactive protein (P = 0.0032) was demonstrated. Conclusions. Higher levels of IL-18 are detected in
active AODS patients and correlate with disease activity and inﬂammatory laboratory features. ROC-AUC analysis of the serum
concentration of IL-18 suggests that it can be considered a diagnostic marker of AOSD. This paper supports the targeting of this
cytokine as a possible therapeutic option in AOSD.
1.Introduction
Adult Onset Still’s Disease (AOSD) is a rare systemic inﬂam-
matory disease of unknown etiology. It is characterized by
a typical clinical triad: high daily spiking fever, evanescent
rash and arthritis or arthralgias, not necessarily present at
the same time. A wide spectrum of other symptoms may
occur: sore throat, lymphoadenopathy, hepatosplenomegaly,
serositis, and myalgias; also pulmonary, cardiovascular, and
kidneymanifestationsmaybepresentoccasionallyrepresent-
ingseverelife-threateningcomplications[1].AOSDhasbeen
described for the ﬁrst time by Bywaters in 1971 [2]w h o
included in this entity all the patients that did not meet cri-
teria of Rheumatoid Arthritis (RA) but showing the typical
manifestations of the systemic form of juvenile rheumatoid
arthritis. Usually, the disease onset is between 16–35 years
[3], women are slightly more aﬀected (M/F = 40/60) [4],
while men have an earlier onset [5]. AOSD pathogenesis is
stillcontroversial:onabackgroundofgeneticpredisposition,
diﬀerent infectious factors seem to act as disease triggers.
Moreover, immunological factors are involved: it has been
recently suggested that an imbalance in cytokine production
by T helper 1 (Th1) versus T helper 2 (Th2) cells is a
key mechanism. In particular, a major production of Th1
cytokines as interleukin (IL)-2, interferon (IFN)-γ and TNF-
α compared with Th2 cytokines (IL-4, IL-5, IL-6 e IL-10) has
been demonstrated [6]. Among all cytokines, IL-18 seems
to play a pivotal role being overexpressed during the course
of disease [7]. However, whether its serum level represents a
marker of disease activity is still controversial [8]. Thus, the
aim of this study was to determine IL-18 serum levels in a
cohort of Italian patients with active and non-active AOSD,
to compare these levels with those obtained from patients
aﬀected with other inﬂammatory diseases and to correlate
them with other known markers of disease activity.2 International Journal of Inﬂammation
2. Methods
Consecutive patients with AOSD (diagnosed according to
Yamaguchy criteria [9]) followed during the last ﬁve years
in the Rheumatology Unit of Sapienza, University of Rome
(Italy), were enrolled. The patients underwent clinical eval-
uation and laboratory analysis. Sera were collected for IL-
18 analysis which was performed by means of ELISA test
(Immuno Pharmacology Research, Italy).
Disease activity at the moment of drawing was estimated
using the criteria proposed by Pouchot in 1991 [10]. The
total score ranges from 0 to 12 and is calculated through
the addition of points assigned to each symptom (fever,
evanescent rash, pleuritis, pneumonia, pericarditis, hep-
atomegaly or abnormal liver function tests, splenomegaly,
lymphadenopathy, WBC > 15000/mm3, sore throat, myal-
gias, and abdominal pain). Active patients were considered
those who presented fever at the moment of drawing with
a Pouchot’s score > 2. For each patient serum ferritin and
C-reactive protein (CRP) serum levels were also determined.
Twenty-one patients with RA, 21 patients with Sjogren’s Syn-
drome (SS), 20 patients with Systemic Lupus Erythematosus
(SLE), and 21 healthy subjects (normal human sera, NHS)
were included in this study as control groups. All subjects,
patients and controls, provided their informed consent.
For the statistical analysis Mann-Whitney U test and
Spearman’s rank correlation test were used. Two-tailed P
values less than 0.05 were considered signiﬁcant. Area
under the receiver operating characteristic curve (ROC-
AUC) analysis was used to evaluate the diagnostic utility of
the IL-18 serum level.
3. Results
Twenty-six patients with AOSD were enrolled (15 males/11
females; mean age 40.6 years, range 23–69 years; mean age at
disease’s onset 32.9 years, range 12–55 years).
Mean disease activity score according to Pouchot’s cri-
teria was 3.8; 16/26 (61%) patients were considered active
presenting fever and a Pouchot’s score > 2. Serum IL-18
mean value in the whole cohort was 461.33pg/mL (range
20.74–6015.00pg/mL).
IL-18 was signiﬁcantly higher in patients with active
AOSD than non-active AOSD (P = 0.001) (Figure 1).
Moreover IL-18 was signiﬁcantly higher in patients with
active AOSD compared with the other control groups (RA
P = 0.0070, SS P = 0.0029, SLE P = 0.0032, NHS
P = 0.0004) (Figure 2, Table 1). Thirteen on 26 (50%)
patients with AOSD and 12/16 (75%) with active AOSD
showed values of serum IL-18 greater than the highest IL-
18 value detected from NHS group. ROC-AUC analysis
of the serum concentration of IL-18 indicated that it was
signiﬁcantly diagnostic of AOSD. The ROC-AUC analysis
for the serum level of the IL-18 between patients with
AOSD and NHS was 0.701 (Figure 3(a)). At a cutoﬀ point of
312.5pg/mL, corresponding to the greatest sum of speciﬁcity
and sensitivity, the speciﬁcity was 61.54% and the sensitivity
was 86.71% for detection of AOSD (likelihood 2.23). The
ROC-AUC analysis for the serum level of the IL-18 between
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Figure 1: Box-and-whisker plot of IL-18 serum levels in patients
with active AOSD (n = 16) and non-active AOSD (n = 10).
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Figure 2: Box-and-whisker plot of IL-18 serum levels in patients
with AOSD (n = 26), RA (n = 21) SS (n = 21), SLE (n = 20),
and NHS (n = 21). Median, quartiles, range, and possibly extreme
values are shown.
patients with AOSD and the other control groups (RA, SS,
SLE) was, respectively, 0.586, 0.565, 0.640 (Figures 3(b),
3(c),a n d3(d)). For RA at a cutoﬀ point of 737pg/mL,
speciﬁcity was 46.15%, sensitivity 80.95% (likelihood 1.50).
For SS at a cutoﬀ point of 766pg/mL speciﬁcity was 46.15%,
sensitivity 95.24% (likelihood 1.77). For SLE at a cutoﬀ
point of 336pg/mL speciﬁcity was 61.54%, sensitivity 70%
(likelihood 1.82).
A signiﬁcant correlation between disease activity and IL-
18 serum levels was observed (P<0.0001, by Spearman’s
rank correlation test) (Figure 4), as well as with serum
ferritin level and CRP (P = 0.0127 and P = 0.0032, resp., by
Spearman’s rank correlation test) (Figures 5(a),a n d5(b)).International Journal of Inﬂammation 3
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Figure 3: Area under the receiver operating characteristic curves for detection of AOSD by reference to the level of serum IL-18. (a) AOSD
versus NHS; (b) AOSD versus RA; (c) AOSD versus SS; (d)AOSD versus SLE.
Table 1: IL-18 serum levels in patients with Adult Onset Still’s Disease (AOSD), Rheumatoid Arthritis (RA), Sjogren’s Syndrome (SS),
Systemic Lupus Erythematosus (SLE), and in normal human sera (NHS).
Active AOSD (n = 16) RA (n = 21) SS (n = 21) SLE (n = 20) NHS (n = 21)
IL-18 (pg/mL) 1220.47 331 368 218.5 189
Range (pg/mL) 43.80–6010 0–2600 147–788 22–1459 0–492
4. Discussion
W ec o n ﬁ r mt h ek e yr o l eo fI L - 1 8a sam a r k e ro fd i s e a s e
activity in AOSD. High serum levels of IL-18 are detected in
AOSD patients with an active disease and its concentration
correlates with disease activity and laboratory features of
inﬂammation. IL-18 is a proinﬂammatory cytokine consid-
ered a member of the IL-1 superfamily with pleiotropic and
immunoregulatory eﬀects. It plays a pivotal role in diﬀerent
inﬂammatory diseases such as RA, Crohn’s disease (CD),
SS, and psoriatic arthritis (PsA) as well as AOSD [7]. It
has been described for the ﬁrst time in 1989 as an inducer
of the production of IFN-γ. In synergy with IL-12 and
IL-15, it induces Th1 maturation and production of other
cytokines as IL-1β,I L - 8 ,M - C S F ,T N F - α,a n dI F N - γ. Despite
its prevalent role on Th1 lineage, it seems to induce and
promote Th2 mediated-eﬀects depending on the diﬀerent
milieuinwhichitplays[11].Besidethisroleintheregulation
of adaptive immune responses, it is involved in inducing
innate immunity. Indeed, it is produced by dendritic cells
(DCs) providing natural killer (NK) cells activation and
driving IFN-γ production by these cells. In turn, NK cells
induce DCs maturation with a further activation of the
adaptive immune response. Thus, IL-18 provides a critical
link between adaptive and innate immune responses and, for
this reason, it can be considered as a rather unique cytokine
[7]. Furthermore, IL-18 can drive angiogenesis [12] and the
production of chemokines, it can upregulate the expression4 International Journal of Inﬂammation
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Figure 4: Correlation between disease activity and IL-18 serum
levels.
ofcostimulatorymoleculesasCD40andCD40L,and,ﬁnally,
it can provoke tissue damage through the activation of
cell-mediated cytotoxicity and the stimulation of the release
of metalloproteases [7]. It is also responsible of an increased
expression of the intercellular adhesion molecule-1 (ICAM-
1) by endothelial cells, representing a possible predictor
of disseminated intravascular coagulation [13]. Moreover,
a recent study has proposed a proapoptotic role for IL-18
that has been associated with the induction of an increased
expression of FasL and p53 on autoreactive lymphocytes in
AOSD [14].Thisevidenceissupportedbythedemonstration
of increased apoptosis of peripheral blood lymphocytes in
AOSD that would be also correlated with disease activity
[14]. This mechanism is deputed to balance the excess of
auto-reactive cells present in peripheral blood in AOSD,
whichisresponsibleofthechronicinﬂammatoryprocess.IL-
18isproducednotonlybymonocyte/macrophagesandDCs,
but also by nonimmune cells, such as intestinal epithelial
cells, keratinocytes, chondrocytes, osteoblasts, and synovial
ﬁbroblasts [7]. For this reason, high values of IL-18 are
detectable not only in serum but also in the synovial
ﬂuid. It has been shown from studies on synovial biopsies
that in AOSD there is an important inﬂammatory process
characterized by the presence of synoviocytes proliferation
with lymphocytes and plasmacells inﬁltrate. Moreover, at
this level, high expression of mRNA codifying for IL-18 can
been detected [15].
In previous studies, we have shown that IL-18 is over-
expressed also in other sites, such as lymph nodes, and liver
[16, 17]. Indeed, an hepatic inﬂammatory process can occur
in approximately 50–75% of the patients, with hepatomegaly
and liver enzymes elevation. It is not surprising that IL-
18 can be produced by Kupﬀer cells and can provoke liver
damage through the activation of NK cells and CD8 cells
[18].
A sa b o v em e n t i o n e d ,I L - 1 8h a sap i v o t a lr o l ei ns e v e r a l
other inﬂammatory conditions such as RA, CD, SS, and
PsA. In RA, high expression of IL-18 by synoviocytes
may upregulate the production of pathogenic cytokines
responsible for the local inﬂammatory process. In SS, IL-
18 is produced by inﬁltrating immune cells surrounding
the ductal structures of the salivary glands, and high levels
of the cytokine have been shown in mucosal biopsies from
CD patients, and in psoriatic lesional skin [7]. Nevertheless,
serum IL-18 reaches the highest levels in AOSD, even from
100 to 1000 folds than in other diseases.
ROC-AUC analysis revealed that AOSD patients could
be discriminated from RA, SLE, and SS patients and from
healthy subjects by the serum level of IL-18 determined by
ELISA. As expected, the largest ROC area was obtained when
comparing AOSD and healthy controls. However, at higher
cutoﬀpoints,IL-18seemstobeabletodiscriminatealsowith
diseases which have increased levels of this cytokine as RA
and SS. These results may suggest that the level of the IL-18
in serum has potential clinical application as a biomarker for
the diagnosis or diﬀerential diagnosis of AOSD.
It has been showed that IL-18 serum levels correlate with
other serological markers of disease activity, such as ferritin,
erythrocytes sedimentation rate, and CRP, and with clinical
manifestations as the occurrence of fever and arthralgias
[17]. On the contrary, Choi coll. [8] did not demonstrate
any signiﬁcant diﬀerences between patients with active and
inactive AOSD, thus the role of IL-18 as a marker of disease
activity is still controversial. In this study a signiﬁcant
correlation between IL-18 and some laboratory markers of
disease activity (ferritin and CRP serum levels) was found.
Indeed,itiswellknownthatserumferritinlevelsaretypically
increased during disease ﬂares and this ﬁnding is useful for
diagnosis and monitoring of disease [1]. Kawashima et al.
in 2001 determined IL-18 serum levels in 16 patients with
AOSD, 34 with RA, 33 with SLE, 19 with systemic sclerosis
(SSc), 21 with polymyositis/dermatomyositis, 28 with SS
and in 53 healthy controls demonstrating, as we did in the
present report, that IL-18 serum concentrations are higher
in AOSD than in all the other conditions [19]. According
to Kawaguchi and coll., IL-18 may be also considered a
marker able to predict the response to therapy [20]. These
authors have observed how patients considered responders
to corticosteroids therapy present lower cytokine levels in
the peripheral blood than nonresponders. This ﬁnding is in
agreement with our observation that IL-18 levels correlate
with disease activity, suggesting that the level may gradually
decrease with therapy.
Nowadays, AOSD therapy is still mostly empirical and
Disease Modifying Antirheumatic Drugs are considered
the ﬁrst-line therapy. In patients refractory to traditional
therapeutic approach, biologic agents have been used with
successful results [21, 22]. Anti-TNF therapy and anti-IL1
and anti-IL-6 agents have been used in an oﬀ-label fashion
with a generally good outcome. Nonetheless, no controlled
randomized trial is available yet. This paper, in agreement
with previous reports, provides further evidence to support
the targeting of IL-18 as a possible therapeutic strategy in
AOSD.International Journal of Inﬂammation 5
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Figure 5: (a) Correlation between CRP serum levels and IL-18 serum levels. (b) Correlation between serum ferritin levels and IL-18 serum
levels.
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